Resolution of vitreomacular traction following intravitreal ranibizumab in cases of ocular toxoplasmosis with choroidal neovascularization
Received 29 July 2013
Accepted for publication 6 September 2013
Published 18 October 2013 Volume 2013:9 Pages 391—394
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Petros Petrou,1,2 Ilias Georgalas,2 Nikolaos Markomichelakis,2 Ioannis Vergados,2 Emanuela Gianakaki,2 Alexander Rouvas2
1Moorfields Eye Hospital, London, UK; 2Ophthalmology Department, University of Athens, Athens, Greece
Purpose: To present the occurrence of the resolution of vitreomacular traction following intravitreal ranibizumab in two patients with inflammatory choroidal neovascular (CNV) membrane with a background of ocular toxoplasmosis.
Methods: Interventional case report.
Results: A 21-year-old Caucasian woman and a 52-year-old Caucasian man both presented with vitreomacular traction with coexistent classic CNV membrane and a background of ocular toxoplasmosis. They both received an intravitreal injection of ranibizumab in an effort to control the underlying CNV membrane. A resolution of the vitreomacular traction was observed within 1 week of the intravitreal injection in both cases.
Conclusion: To the best of our knowledge, this is the first reported case of vitreomacular traction resolution in two patients with ocular toxoplasmosis following ranibizumab administration. Of course, further studies are needed in order to adequately support this association.
Keywords: vitreomacular traction, spontaneous resolution, ranibizumab, intravitreal, inflammation
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.